Treatment for Low-Grade Level II Astrocytoma

SutNut Member Posts: 3
edited March 2014 in Brain Cancer #1
I had 4 brain surgeries to remove my tumor in 2005. My doctor is wanting me to begin Temodar at this time. What treatment have many of you undergone who have had the same grade of brain tumor?


  • margin
    margin Member Posts: 8
    8 yrs ago diagnosed w/class 2 asytrocytoma.had gammaknife radiation, no surgery. this july tumor went to between level 3 & 4 and was removed at crawford long/emory hospital in atl, ga. I will have my 30th radiation treatment tomorrow and took the temodar for 1 month every night during the beginning of the radiation treatments. after one month developed bad rash and had to stop the temodar. I took neausea meds 30 mins before taking temodar and it did not make me sick as long as I took it with plenty of water. if I woke up with heartburn tums did the trick. you can always try the temodar, what do you have to loose. Good luck and I will keep you in my prayers.God gave me a 2nd chance and I am healed. He can do the same for you. God Bless
  • Felixthecat
    Felixthecat Member Posts: 37
    Here's the latest information on hormone receptor status of astrocytomas. There is a progesterone antagonist that could be used if other treatment's fail but that drug is only available via the US FMF program for compassionate use.

    2001: Progesterone receptor isoforms expression pattern in human astrocytomas
    • Progesterone receptors (PR) have been detected in human astrocytomas; however, the expression pattern of PR isoforms in these brain tumors is unknown. Progesterone receptor isoforms expression was studied in 13 biopsies of astrocytomas (6 grade III, and 7 grade IV) from adult Mexican patients by using reverse transcription-polymerase chain reaction and immunohistochemistry. Progesterone receptor expression was observed at mRNA and at protein levels in 66% and 83% of astrocytomas grade III, respectively, whereas 100% of astrocytomas grade IV expressed PR. Almost all PR mRNA content in astrocytomas grades III and IV corresponded to PR-B. The number of immunoreactive cells expressing PR-B was higher than that expressing PR-A in 73% of the cases. Estrogen receptor-á protein was only observed in 33% of astrocytomas grade III, whereas no astrocytomas grade IV expressed it. These data suggest that PR-B is the predominant isoform expressed in human astrocytomas grades III and IV, and that estrogen receptor-á is not expressed in astrocytomas grade IV.